| Item Type | Name |
|
Concept
|
Arabinofuranosylcytosine Triphosphate
|
|
Concept
|
Cytarabine
|
|
Academic Article
|
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
|
|
Academic Article
|
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
|
|
Academic Article
|
Pharmacologically directed design of leukemia therapy.
|
|
Academic Article
|
Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.
|
|
Academic Article
|
Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells.
|
|
Academic Article
|
High-dose cytosine arabinoside in multiple myeloma.
|
|
Academic Article
|
Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
|
|
Academic Article
|
Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
|
|
Academic Article
|
In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia.
|
|
Academic Article
|
Evolution of the arabinosides and the pharmacology of fludarabine.
|
|
Academic Article
|
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
|
|
Academic Article
|
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
|
|
Academic Article
|
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
|
|
Academic Article
|
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
|
|
Academic Article
|
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
|
|
Academic Article
|
The utilization of nucleotides by animal cells.
|
|
Academic Article
|
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
|
|
Academic Article
|
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
|
|
Academic Article
|
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
|
|
Academic Article
|
9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
|
|
Academic Article
|
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
|
|
Academic Article
|
Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine.
|
|
Academic Article
|
Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.
|
|
Academic Article
|
Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
|
|
Academic Article
|
Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.
|
|
Academic Article
|
Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
|
|
Academic Article
|
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
|
|
Academic Article
|
Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
|
|
Academic Article
|
High-dose cytosine arabinoside in non-Hodgkin's lymphoma.
|
|
Academic Article
|
Modulation of arabinosylcytosine metabolism during leukemia therapy.
|
|
Academic Article
|
High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
|
|
Academic Article
|
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
|
|
Academic Article
|
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
|
|
Academic Article
|
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
|
|
Academic Article
|
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
|
|
Academic Article
|
Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
|
|
Academic Article
|
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
|
|
Academic Article
|
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
|
|
Academic Article
|
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
|
|
Academic Article
|
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
|
|
Academic Article
|
Correspondence Re: L.E. Damon et al., Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res., 51: 4141-4145, 1991.
|
|
Academic Article
|
Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity.
|
|
Academic Article
|
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
|
|
Academic Article
|
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
|
|
Academic Article
|
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
|
|
Academic Article
|
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
|
|
Academic Article
|
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
|
|
Academic Article
|
Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
|
|
Academic Article
|
Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.
|
|
Academic Article
|
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
|
|
Academic Article
|
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
|
|
Academic Article
|
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.
|
|
Academic Article
|
Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
|
|
Academic Article
|
Pharmacologically directed ara-C therapy for refractory leukemia.
|
|
Academic Article
|
Clinical experience with fludarabine in leukaemia.
|
|
Academic Article
|
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
|
|
Academic Article
|
Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells.
|
|
Academic Article
|
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Cellular pharmacodynamics of anticancer drugs.
|
|
Academic Article
|
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
|
|
Academic Article
|
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
|
|
Academic Article
|
Intracellular pharmacodynamics in leukemia therapy.
|
|
Academic Article
|
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
|
|
Academic Article
|
Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
|
|
Academic Article
|
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
|
|
Academic Article
|
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
|
|
Academic Article
|
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
|
|
Academic Article
|
Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
|
|
Academic Article
|
Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
|
|
Academic Article
|
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
|
|
Academic Article
|
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
|
|
Academic Article
|
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
|
|
Academic Article
|
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
|
Academic Article
|
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
|
|
Academic Article
|
Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
|
|
Academic Article
|
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.
|
|
Academic Article
|
High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
|
|
Academic Article
|
Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
|
|
Academic Article
|
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
|
|
Academic Article
|
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
|
|
Academic Article
|
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
|
|
Academic Article
|
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
|
|
Academic Article
|
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
|
|
Academic Article
|
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
|
|
Academic Article
|
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
|
|
Academic Article
|
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
|
|
Academic Article
|
Clofarabine in leukemia.
|
|
Academic Article
|
The expanding role of fludarabine in hematologic malignancies.
|
|
Academic Article
|
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
|
|
Academic Article
|
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
|
|
Academic Article
|
Cellular concentrations of dATP and ara-ATP in peripheral blood leukemic cells (PBC) and erythrocytes (RBC) from patients treated with deoxycoformycin (dCF) or arabinosyladenine (ara-A)
|
|
Academic Article
|
The effect of deoxycoformycin (dCF) on the toxicity and metabolism of 9-β-D-arabinofuranosyladenine (ARA-A) and its 5'-triphosphate (ARA-ATP) in CHO cells
|
|
Academic Article
|
Relationship between ARA-ATP concentration, DNA synthetic capacity (DSC) and viability in CHO cells
|
|
Academic Article
|
In vivo cellular kinetics and pharmacology studies of ARA-C and 3-DAU chemotherapy for relapsing adult acute leukemia
|
|
Academic Article
|
Biochemical basis of the increased arabinosyladenine (ARA A) activity in the presence of adenosine deaminase inhibitors (ADI)
|
|
Academic Article
|
Comparison of the metabolism, kinetics, and inhibitory action of arabinosyl-2-fluoroadenine (F-ara-A) and its 5'-monophosphate (F-ara-AMP) in tumor bearing mice
|
|
Academic Article
|
Comparison of the action of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ARA-A) with 9-β-D-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells 9-β-Arabinofuranosyladenine (ARA-A) in CCRF-CEM cells
|
|
Academic Article
|
Intracellular metabolism and action of an antitumor nucleoside, 2'-C- cyano-2'-deoxy-1-β-D-arabinofuranosylcytosine (CNDAC)
|
|
Academic Article
|
Cellular pharmacology of arabinosylcytosine 5'-triphosphate (araCTP) in leukemic cells during high-dose araC therapy
|
|
Academic Article
|
Detection and quantitation of ARA-C 5'-triphosphate (ARA-CTP) in the leukemic cells of adult AML patients treated with ARA-C
|
|
Academic Article
|
Biochemical basis of the therapeutic efficacy of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A)
|